<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcinfectdis&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Infectious Diseases - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcinfectdis/</link>
        <description>The most accessed research articles published by BMC Infectious Diseases</description>
        <dc:date>2009-11-11T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/166" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/173" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/174" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/172" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/177" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/176" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/171" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/175" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/6/130" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/169" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/166">
        <title>Initial psychological responses to Influenza A, H1N1 (&quot;Swine flu&quot;)</title>
        <description>Background:
The outbreak of the pandemic flu, Influenza A H1N1 (Swine Flu) in early 2009, provided a major challenge to health services around the world. Previous pandemics have led to stockpiling of goods, the victimisation of particular population groups, and the cancellation of travel and the boycotting of particular foods (e.g. pork). We examined initial behavioural and attitudinal responses towards Influenza A, H1N1 (&quot;Swine flu&quot;) in the six days following the WHO pandemic alert level 5, and regional differences in these responses.
Methods:
328 respondents completed a cross-sectional Internet or paper-based questionnaire study in Malaysia (N = 180) or Europe (N = 148). Measures assessed changes in transport usage, purchase of preparatory goods for a pandemic, perceived risk groups, indicators of anxiety, assessed estimated mortality rates for seasonal flu, effectiveness of seasonal flu vaccination, and changes in pork consumption
Results:
26% of the respondents were &apos;very concerned&apos; about being a flu victim (42% Malaysians, 5% Europeans, p &lt; .001). 36% reported reduced public transport use (48% Malaysia, 22% Europe, p &lt; .001), 39% flight cancellations (56% Malaysia, 17% Europe, p &lt; .001). 8% had purchased preparatory materials (e.g. face masks: 8% Malaysia, 7% Europe), 41% Malaysia (15% Europe) intended to do so (p &lt; .001). 63% of Europeans, 19% of Malaysians had discussed the pandemic with friends (p &lt; .001). Groups seen as at &apos;high risk&apos; of infection included the immune compromised (mentioned by 87% respondents), pig farmers (70%), elderly (57%), prostitutes/highly sexually active (53%), and the homeless (53%). In data collected only in Europe, 64% greatly underestimated the mortality rates of seasonal flu, 26% believed seasonal flu vaccination gave protection against swine flu. 7% had reduced/stopped eating pork. 3% had purchased anti-viral drugs for use at home, while 32% intended to do so if the pandemic worsened.
Conclusion:
Initial responses to Influenza A show large regional differences in anxiety, with Malaysians more anxious and more likely to reduce travel and to buy masks and food. Discussions with family and friends may reinforce existing anxiety levels. Particular groups (homosexuals, prostitutes, the homeless) are perceived as at greater risk, potentially leading to increased prejudice during a pandemic. Europeans underestimated mortality of seasonal flu, and require more information about the protection given by seasonal flu inoculation.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/166</link>
                <dc:creator>Robin Goodwin</dc:creator>
                <dc:creator>Shamsul Haque</dc:creator>
                <dc:creator>Felix Neto</dc:creator>
                <dc:creator>Lynn Myers</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:166</dc:source>
        <dc:date>2009-10-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-166</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>166</prism:startingPage>
        <prism:publicationDate>2009-10-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/173">
        <title>Acute sensorineural hearing loss and severe otalgia due to scrub typhus </title>
        <description>Background:
Scrub typhus is an acute febrile illness caused by Orientia tsutsugamushi.Case presentationsWe encountered a patient with sensorineural hearing loss complicating scrub typhus, and three patients with scrub typhus who complained of otalgia, which was sudden onset, severe, paroxysmal, intermittent yet persistent pain lasting for several seconds, appeared within 1 week after the onset of fever and rash. The acute sensorineural hearing loss and otalgia were resolved after antibiotic administration.
Conclusion:
When patients in endemic areas present with fever and rash and have sensorineural hearing loss or otalgia without otoscopic abnormalities, clinicians should suspect scrub typhus and consider empirical antibiotic therapy.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/173</link>
                <dc:creator>Ji-In Kang</dc:creator>
                <dc:creator>Dong-Min Kim</dc:creator>
                <dc:creator>Jun Han Lee</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:173</dc:source>
        <dc:date>2009-10-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-173</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>173</prism:startingPage>
        <prism:publicationDate>2009-10-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/174">
        <title>Downregulation of MIP-1alpha/CCL3 with praziquantel treatment in Schistosoma haematobiumand HIV-1 co-infected individuals in a rural community in Zimbabwe</title>
        <description>Background:
Chemokines have been reported to play an important role in granulomatous inflammation during Schistosoma mansoni infection. However there is less information on their role in Schistosoma haematobium infection, or on the effect of concurrent HIV-1 infection, as a potential modifying influence.
Methods:
To determine levels of MIP-1&#945;/CCL3 chemokine in plasma of S. haematobium and HIV-1 co-infected and uninfected individuals in a rural black Zimbabwean community.A cohort was established of HIV-1 and schistosomiasis infection and co-infection comprising 379 participants. Outcome measures consisted of HIV-1 and schistosomiasis status and levels of MIP-1&#945;/CCL3 in plasma at baseline and three months post treatment. An association was established between MIP-1&#945;/CCL3 plasma levels with HIV-1 and S. haematobium infections.
Results:
A total of 379 adults formed the established cohort comprising 76 (20%) men and 303 (80%) women. Mean age was 33.25, range 17 - 62 years. The median MIP-1&#945;/CCL3 plasma concentration was significantly higher in S. haematobium infected compared with uninfected individuals (p = 0.029). In contrast, there was no difference in the median MIP-1&#945;/CCL3 levels between HIV-1 positive and negative individuals (p = 0.631). MIP-1&#945;/CCL3 concentration in plasma was significantly reduced at three months after treatment with praziquantel (p = 000).
Conclusion:
The results of our study show that the MIP-1&#945;/CCL3 levels were positively associated with S. haematobium egg counts at baseline but not with HIV-1 infection status. MIP-1&#945;/CCL3 levels were significantly reduced at three months post treatment with praziquantel. We therefore conclude that MIP-1&#945;/CCL3 is produced during infection with S haematobium. S. haematobium infection is associated with increased MIP-1&#945;/CCL3 levels in an egg intensity-dependent manner and treatment of S. haematobium is associated with a reduction in MIP-1&#945;/CCL3.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/174</link>
                <dc:creator>R Zinyama-Gutsire</dc:creator>
                <dc:creator>E Gomo</dc:creator>
                <dc:creator>P Kallestrup</dc:creator>
                <dc:creator>C Erickstrup</dc:creator>
                <dc:creator>H Ullum</dc:creator>
                <dc:creator>A Butterworth</dc:creator>
                <dc:creator>S Munyati</dc:creator>
                <dc:creator>T Mduluza</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:174</dc:source>
        <dc:date>2009-10-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-174</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>174</prism:startingPage>
        <prism:publicationDate>2009-10-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/172">
        <title>Immune control of HIV-1 infection after
therapy interruption: immediate versus deferred antiretroviral therapy</title>
        <description>Background:
The optimal stage for initiating antiretroviral therapies in HIV-1 bearing patients is still a matter of debate.
Methods:
We present computer simulations of HIV-1 infection aimed at identifying the pro et contra of immediate as compared to deferred Highly Active Antiretroviral Therapy (HAART).
Results:
Our simulations highlight that a prompt specific CD8+ cytotoxic T lymphocytes response is detected when therapy is delayed. Compared to very early initiation of HAART, in deferred treated patients CD8+ T cells manage to mediate the decline of viremia in a shorter time and, at interruption of therapy, the virus experiences a stronger immune pressure. We also observe, however, that the immunological effects of the therapy fade with time in both therapeutic regimens. Thus, within one year from discontinuation, viral burden recovers to the value at which it would level off in the absence of therapy.In summary, simulations show that immediate therapy does not prolong the disease-free period and does not confer a survival benefit when compared to treatment started during the chronic infection phase.
Conclusion:
Our conclusion is that, since there is no therapy to date that guarantees life-long protection, deferral of therapy should be preferred in order to minimize the risk of adverse effects, the occurrence of drug resistances and the costs of treatment.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/172</link>
                <dc:creator>Paola Paci</dc:creator>
                <dc:creator>Rossella Carello</dc:creator>
                <dc:creator>Massimo Bernaschi</dc:creator>
                <dc:creator>Gianpiero D'Offizi</dc:creator>
                <dc:creator>Filippo Castiglione</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:172</dc:source>
        <dc:date>2009-10-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-172</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>172</prism:startingPage>
        <prism:publicationDate>2009-10-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/177">
        <title>PCR melting profile (PCR MP) - a new tool for differentiation of Candida albicans strains</title>
        <description>Background:
We have previously reported the use of PCR Melting Profile (PCR MP) technique based on using low denaturation temperatures during ligation mediated PCR (LM PCR) for bacterial strain differentiation. The aim of the current study was to evaluate this method for intra-species differentiation of Candida albicans strains.
Methods:
In total 123 Candida albicans strains (including 7 reference, 11 clinical unrelated, and 105 isolates from patients of two hospitals in Poland) were examined using three genotyping methods: PCR MP, macrorestriction analysis of the chromosomal DNA by pulsed-field gel electrophoresis (REA-PFGE) and RAPD techniques.
Results:
The genotyping results of the PCR MP were compared with results from REA-PFGE and RAPD techniques giving 27, 26 and 25 unique types, respectively. The results showed that the PCR MP technique has at least the same discriminatory power as REA-PFGE and RAPD.
Conclusion:
Data presented here show for the first time the evaluation of PCR MP technique for candidial strains differentiation and we propose that this can be used as a relatively simple and cheap technique for epidemiological studies in short period of time in hospital.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/177</link>
                <dc:creator>Beata Krawczyk</dc:creator>
                <dc:creator>Justyna Leibner-Ciszak</dc:creator>
                <dc:creator>Anna Mielech</dc:creator>
                <dc:creator>Magdalena Nowak</dc:creator>
                <dc:creator>Jozef Kur</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:177</dc:source>
        <dc:date>2009-11-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-177</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>177</prism:startingPage>
        <prism:publicationDate>2009-11-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/176">
        <title>Evaluation of routinely reported surgical site infections against microbiological culture results: a tool to identify patient groups where diagnosis and treatment may be improved.</title>
        <description>Background:
Surgeons may improve their decision making by assessing the extent to which their initial clinical diagnosis of a surgical site infection (SSI) was supported by culture results. Aim of the present study was to evaluate routinely reported SSI by surgeons against microbiological culture results, to identify patient groups with lower agreement where decision making may be improved.
Methods:
701 admissions with SSI were reported by surgeons in a university medical centre in the period 1997-2005, which were retrospectively checked for microbiological culture results. Reporting a SSI was conditional on treatment being given (e.g. antibiotics) and was classified by severity. To identify specific patient groups, patients were classified according to the surgery group of the first operation during admission (e.g. trauma).
Results:
Of all reported SSI, 523 (74.6%) had a positive culture result, 102 (14.6%) a negative culture result and 76 (10.8%) were classified as unknown culture result (due to no culture taken). Given a known culture result, reported SSI with positive culture results less often concerned trauma patients (16% versus 26%, X2 = 4.99 p = 0.03) and less severe SSI (49% versus 85%, X2 = 10.11 p &lt; 0.01) suggesting that a more conservative approach may be warranted in these patients. The trauma surgeons themselves perceived to have become too liberal in administering antibiotics (and reporting SSI).
Conclusion:
Routine reporting of SSI was mostly supported by culture results. However, this support was less often found in trauma patients and less severe SSI, thereby giving surgeons feedback that diagnosis and treatment may be improved in these cases.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/176</link>
                <dc:creator>Marco Krukerink</dc:creator>
                <dc:creator>Job Kievit</dc:creator>
                <dc:creator>Perla Marang-van de Mheen</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:176</dc:source>
        <dc:date>2009-11-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-176</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>176</prism:startingPage>
        <prism:publicationDate>2009-11-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/171">
        <title>Newly formed cystic lesions for the development of pneumomediastinum in Pneumocystis jirovecii pneumonia</title>
        <description>Background:
Pneumocystis jirovecii, formerly named Pneumocystis carinii, is one of the most common opportunistic infections in human immunodeficiency virus (HIV)-infected patients.Case presentationsWe encountered two cases of spontaneous pneumomediastinum with subcutaneous emphysema in HIV-infected patients being treated for Pneumocystis jirovecii pneumonia with trimethoprim/sulfamethoxazole.
Conclusion:
Clinicians should be aware that cystic lesions and bronchiectasis can develop in spite of trimethoprim/sulfamethoxazole treatment for P. jirovecii pneumonia. The newly formed bronchiectasis and cyst formation that were noted in follow up high resolution computed tomography (HRCT) but were not visible on HRCT at admission could be risk factors for the development of pneumothorax or pneumomediastinum with subcutaneous emphysema in HIV-patients.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/171</link>
                <dc:creator>Ju-Yeon Cho</dc:creator>
                <dc:creator>Dong-Min Kim</dc:creator>
                <dc:creator>Yong Eun Kwon</dc:creator>
                <dc:creator>Sung Ho Yoon</dc:creator>
                <dc:creator>Seung Il Lee</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:171</dc:source>
        <dc:date>2009-10-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-171</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>171</prism:startingPage>
        <prism:publicationDate>2009-10-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/175">
        <title>Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: Demand, supply and seasonality.</title>
        <description>Background:
In February 2005, the US Advisory Committee on Immunization Practices recommended the new meningococcal conjugate vaccine (MCV4) for routine use among 11- to 12-year-olds (at the preadolescent health-care visit), 14- to 15-year-olds (before high-school entry), and groups at increased risk. Vaccine distribution started in March; however, in July, the manufacturer reported inability to meet demand and widespread MCV4 shortages were reported. Our objectives were to determine early uptake patterns among target (11-12 and 14-15 year olds) and non-target (13- plus 16-year-olds) age groups. A post hoc analysis was conducted to compare seasonal uptake patterns of MCV4 with polysaccharide meningococcal (MPSV4) and tetanus diphtheria (Td) vaccines.
Methods:
We analyzed data for adolescents 11-16 years from five managed care organizations participating in the Vaccine Safety Datalink (VSD). For MCV4, we estimated monthly and cumulative coverage during 2005 and calculated risk ratios. For MPSV4 and Td, we combined 2003 and 2004 data and compared their seasonal uptake patterns with MCV4.
Results:
Coverage for MCV4 during 2005 among the 623,889 11-16 years olds was 10%. Coverage for 11-12 and 14-15 year olds was 12% and 11%, respectively, compared with 8% for 13- plus 16-year-olds (p &lt; 0.001). Of the 64,272 MCV4 doses administered from March-December 2005, 73% were administered June-August. Fifty-nine percent of all MPSV4 doses and 38% of all Td doses were administered during June-August.
Conclusion:
A surge in vaccine uptake between June and August was observed among adolescents for MCV4, MPSV4 and Td vaccines. The increase in summer-time vaccinations and vaccination of non-targeted adolescents coupled with supply limitations likely contributed to the reported shortages of MCV4 in 2005.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/175</link>
                <dc:creator>Suchita Lorick</dc:creator>
                <dc:creator>Daniel Fishbein</dc:creator>
                <dc:creator>Eric Weintraub</dc:creator>
                <dc:creator>Pascale Wortley</dc:creator>
                <dc:creator>Grace Lee</dc:creator>
                <dc:creator>Fangjun Zhou</dc:creator>
                <dc:creator>Robert Davis</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:175</dc:source>
        <dc:date>2009-11-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-175</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>175</prism:startingPage>
        <prism:publicationDate>2009-11-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/6/130">
        <title>How long do nosocomial pathogens persist on inanimate surfaces? A systematic review</title>
        <description>Background:
Inanimate surfaces have often been described as the source for outbreaks of nosocomial infections. The aim of this review is to summarize data on the persistence of different nosocomial pathogens on inanimate surfaces.
Methods:
The literature was systematically reviewed in MedLine without language restrictions. In addition, cited articles in a report were assessed and standard textbooks on the topic were reviewed. All reports with experimental evidence on the duration of persistence of a nosocomial pathogen on any type of surface were included.
Results:
Most gram-positive bacteria, such as Enterococcus spp. (including VRE), Staphylococcus aureus (including MRSA), or Streptococcus pyogenes, survive for months on dry surfaces. Many gram-negative species, such as Acinetobacter spp., Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, Serratia marcescens, or Shigella spp., can also survive for months. A few others, such as Bordetella pertussis, Haemophilus influenzae, Proteus vulgaris, or Vibrio cholerae, however, persist only for days. Mycobacteria, including Mycobacterium tuberculosis, and spore-forming bacteria, including Clostridium difficile, can also survive for months on surfaces. Candida albicans as the most important nosocomial fungal pathogen can survive up to 4 months on surfaces. Persistence of other yeasts, such as Torulopsis glabrata, was described to be similar (5 months) or shorter (Candida parapsilosis, 14 days). Most viruses from the respiratory tract, such as corona, coxsackie, influenza, SARS or rhino virus, can persist on surfaces for a few days. Viruses from the gastrointestinal tract, such as astrovirus, HAV, polio- or rota virus, persist for approximately 2 months. Blood-borne viruses, such as HBV or HIV, can persist for more than one week. Herpes viruses, such as CMV or HSV type 1 and 2, have been shown to persist from only a few hours up to 7 days.
Conclusion:
The most common nosocomial pathogens may well survive or persist on surfaces for months and can thereby be a continuous source of transmission if no regular preventive surface disinfection is performed.</description>
        <link>http://www.biomedcentral.com/1471-2334/6/130</link>
                <dc:creator>Axel Kramer</dc:creator>
                <dc:creator>Ingeborg Schwebke</dc:creator>
                <dc:creator>Gunter Kampf</dc:creator>
                <dc:source>BMC Infectious Diseases 2006, 6:130</dc:source>
        <dc:date>2006-08-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-6-130</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>130</prism:startingPage>
        <prism:publicationDate>2006-08-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/169">
        <title>Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis</title>
        <description>Background:
Successful antiretroviral treatment programs in rural sub-Saharan Africa may face different challenges than programs in urban areas. The objective of this study was to identify patient characteristics, barriers to care, and treatment responses of HIV-infected children seeking care in rural Zambia.
Methods:
Cross-sectional analysis of HIV-infected children seeking care at Macha Hospital in rural southern Zambia. Information was collected from caretakers and medical records.
Results:
192 HIV-infected children were enrolled from September 2007 through September 2008, 28% of whom were receiving antiretroviral therapy (ART) at enrollment. The median age was 3.3 years for children not receiving ART (IQR 1.8, 6.7) and 4.5 years for children receiving ART (IQR 2.7, 8.6). 91% travelled more than one hour to the clinic and 26% travelled more than 5 hours. Most participants (73%) reported difficulties accessing the clinic, including insufficient money (60%), lack of transportation (54%) and roads in poor condition (32%). The 54 children who were receiving ART at study enrollment had been on ART a median of 8.6 months (IQR: 2.7, 19.5). The median percentage of CD4+ T cells was 12.4 (IQR: 9.2, 18.6) at the start of ART, and increased to 28.6 (IQR: 23.5, 36.1) at the initial study visit. However, the proportion of children who were underweight decreased only slightly, from 70% at initiation of ART to 61% at the initial study visit.
Conclusion:
HIV-infected children in rural southern Zambia have long travel times to access care and may have poorer weight gain on ART than children in urban areas. Despite these barriers, these children had a substantial rise in CD4+ T cell counts in the first year of ART although longer follow-up may indicate these gains are not sustained.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/169</link>
                <dc:creator>Janneke van Dijk</dc:creator>
                <dc:creator>Catherine Sutcliffe</dc:creator>
                <dc:creator>Bornface Munsanje</dc:creator>
                <dc:creator>Francis Hamangaba</dc:creator>
                <dc:creator>Philip Thuma</dc:creator>
                <dc:creator>William Moss</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:169</dc:source>
        <dc:date>2009-10-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-169</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>169</prism:startingPage>
        <prism:publicationDate>2009-10-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
